# Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors

> **NCT01966445** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 29 (actual)

## Conditions studied

- Cancer
- Neoplasms

## Interventions

- **BIOLOGICAL:** GSK2849330

## Key facts

- **NCT ID:** NCT01966445
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-26
- **Primary completion:** 2017-09-18
- **Final completion:** 2017-09-18
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2019-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01966445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01966445, "Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01966445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*